Author:
Zhang Li-han,Yang Ai-jun,Wang Min,Liu Wei,Wang Chen-yu,Xie Xiao-feng,Chen Xu,Dong Jing-fei,Li Min
Funder
National Natural Science Foundation of China
Science and Technology Support Program of Gansu Province
the Program for Changjiang Scholars and Innovative Research Team in University
the Fundamental Research Funds for the Central Universities
National Institutes of Health
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Biochemistry, medical,Cell Biology,Clinical Biochemistry,Pharmaceutical Science,Pharmacology
Reference40 articles.
1. Foulkes WD, Smith IE, Reis-Filho JS (2010) Triple-negative breast cancer. N Engl J Med 363(20):1938–1948. doi:
10.1056/NEJMra1001389
2. Irshad S, Ellis P, Tutt A (2011) Molecular heterogeneity of triple-negative breast cancer and its clinical implications. Curr Opin Oncol 23(6):566–577
3. Carey LA (2010) Directed therapy of subtypes of triple-negative breast cancer. Oncologist 15(Supplement 5):49–56
4. Metzger-Filho O, Tutt A, de Azambuja E, Saini KS, Viale G, Loi S, Bradbury I, Bliss JM, Azim HA Jr, Ellis P, Di Leo A, Baselga J, Sotiriou C, Piccart-Gebhart M (2012) Dissecting the heterogeneity of triple-negative breast cancer. J Clin Oncol 30(15):1879–1887
5. Kovalev AA, Tsvetaeva DA, Grudinskaja TV (2013) Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer. Exp Oncol 35(4):287–290
Cited by
43 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献